Avery Catlin
Directeur/Membre du Conseil chez CORBUS PHARMACEUTICALS HOLDINGS, INC.
Fortune : 196 838 $ au 30/06/2024
Profil
Avery W.
Catlin is currently a Director at Corbus Pharmaceuticals, Inc. and an Independent Director at Corbus Pharmaceuticals Holdings, Inc. He is also a Vice President at CuraGen Corp.
Previously, he served as an Independent Director at Provention Bio, Inc. from 2018 to 2023.
He was the Chief Financial Officer at MediSense, Inc., Repligen Corp., Endogen, Inc., AVANT Immunotherapeutics, Inc., and Celldex Therapeutics, Inc. He holds an undergraduate degree from the University of Virginia and an MBA from Babson College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/05/2024 | 4 350 ( 0,04% ) | 196 838 $ | 30/06/2024 |
Postes actifs de Avery Catlin
| Sociétés | Poste | Début |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Directeur/Membre du Conseil | 01/08/2014 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Corporate Officer/Principal | - |
Corbus Pharmaceuticals, Inc.
 Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Avery Catlin
| Sociétés | Poste | Fin |
|---|---|---|
| PROVENTION BIO, INC. | Directeur/Membre du Conseil | 27/04/2023 |
| CELLDEX THERAPEUTICS, INC. | Directeur Financier/CFO | 30/06/2017 |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Directeur Financier/CFO | 01/10/2008 |
Endogen, Inc.
 Endogen, Inc. Medical SpecialtiesHealth Technology Part of Thermo Fisher Scientific, Inc., Endogen, Inc. is a company that specializes in producing reagents and immuno-assay test kits. The company is based in Cambridge, MA. Endogen was acquired by Perbio Science AB, part of Thermo Fisher Scientific, Inc. from September 24, 2003 on July 08, 1999 for $14.77 million. | Directeur Financier/CFO | 01/01/1999 |
| REPLIGEN CORPORATION | Directeur Financier/CFO | 01/01/1996 |
Formation de Avery Catlin
| University of Virginia | Undergraduate Degree |
| Babson College | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Endogen, Inc.
Endogen, Inc. Medical SpecialtiesHealth Technology Part of Thermo Fisher Scientific, Inc., Endogen, Inc. is a company that specializes in producing reagents and immuno-assay test kits. The company is based in Cambridge, MA. Endogen was acquired by Perbio Science AB, part of Thermo Fisher Scientific, Inc. from September 24, 2003 on July 08, 1999 for $14.77 million. | Health Technology |
MediSense, Inc.
 MediSense, Inc. Medical SpecialtiesHealth Technology MediSense, Inc. provides blood-glucose monitoring systems. Its products are used to monitor sugar levels in diabetes people. The company was founded in 1996 and is located in Bedford, MA | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Corbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Health Technology |
